Such cancers might be very sensitive to inhibition of ERBB2-ERBB3 [13], and there are several recent reports of good responses in patients to anti-ERBB2 or anti-ERBB3 therapy, including anti-ERBB3 antibody and HER-family kinase inhibitors such as the pan-ERBB inhibitor afatinib. Here, ERBB3 is linked to cancer.